These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12352941)

  • 1. Simultaneous determination of rifampicin and efavirenz in plasma.
    Boffito M; Tija J; Reynolds HE; Hoggard PG; Bonora S; Di Perri G; Back DJ
    Ther Drug Monit; 2002 Oct; 24(5):670-4. PubMed ID: 12352941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Vibhagool A; Kiertiburanakul S; Rattanasiri S; Prasithsirikul W; Sankote J; Mahanontharit A; Ruxrungtham K
    AIDS; 2005 Sep; 19(14):1481-6. PubMed ID: 16135901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G; Khoo S; Jack C; Lalloo U
    J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
    Fox D; O'Connor R; Mallon P; McMahon G
    J Pharm Biomed Anal; 2011 Dec; 56(4):785-91. PubMed ID: 21840662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
    Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
    Kappelhoff BS; Rosing H; Huitema AD; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 792(2):353-62. PubMed ID: 12860043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N; Purwantyastuti ; Instiaty ; Rusli A
    Acta Med Indones; 2016 Jan; 48(1):10-6. PubMed ID: 27241539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
    Marzolini C; Telenti A; Buclin T; Biollaz J; Decosterd LA
    J Chromatogr B Biomed Sci Appl; 2000 Mar; 740(1):43-58. PubMed ID: 10798293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Shah I; Swaminathan S; Ramachandran G; Kumar AK; Goray A; Chaddha U; Tayal S; Lala M
    Indian Pediatr; 2011 Dec; 48(12):943-7. PubMed ID: 21555806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.